First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Shaan Dudani, Daniel Yick Chin Heng, Marco Iafolla et al.|Journal of Clinical Oncology|2019Cited by 5
Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).Austin Kalirai, Naveen S. Basappa, Lori Wood et al.|Journal of Clinical Oncology|2019Cited by 3
Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.Marie-France Savard, Daniel Yick Chin Heng, J. Connor Wells et al.|Journal of Clinical Oncology|2019Cited by 1
First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).Shaan Dudani, Daniel Yick Chin Heng, Jeffrey Graham et al.|Journal of Clinical Oncology|2019Cited by 1